继发性甲状旁腺机能亢进的诊疗进展

doi:10.6040/j.issn.1673-3770.1.2016.10

摘要/Abstract

摘要： 继发性甲状旁腺机能亢进(SHPT)是慢性肾功能不全(CKD)代谢紊乱所致的一类常见并发症,发病率逐年升高,临床表现为甲状旁腺激素(PTH)升高,伴有钙磷代谢紊乱、骨痛等症状。CKD继发甲状旁腺机能亢进的发病机制,除了熟知的因素(包括血钙血磷、维生素D及其受体、钙敏感受体等)以外,还涉及分子和细胞机制,如肽酰脯氨酰顺反异构酶1(Pin1)、抗衰老蛋白Klotho、成纤维细胞生长因子23等。目前治疗SHPT的主要方法有药物治疗、外科手术治疗和介入治疗,对手术治疗的术前定位和手术术式进行综述。

关键词: 继发性甲状旁腺功能亢进, 定位, 治疗

Abstract: Secondary hyperparathyroidism(SHPT)is a common complication of metabolic disorders in chronic kidney disease(CKD)patients. The Incidence of SHPT has increased with the passing years and the clinical manifestations are increased parathyroid hormone level, calcium-phosphorus metabolic disorders and bone pain, et al. In addition to the familiar factors, such as serum calcium and phosphorus, vitamin D and its receptor, calcium-sensing receptors, the mechanism for CKD-SHPT also includes the molecular and cellular mechanism, such as peptidyl-prolyl cis-trans isomerase 1(Pin1), Klotho protein and fibroblast growth factor-23(FGF23). Nowadays, the therapeutic strategy is mainly focused on medication, surgery and interventional therapy. This review will also introduce the pre-operation localization methods and surgical methods. Its critical to choose the suitable surgical methods for SHPT treatment.

Key words: Localization, Secondary hyperparathyroidism, Treatment

中图分类号:

R582.2

陈隽,王家东. 继发性甲状旁腺机能亢进的诊疗进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 36-39.

CHEN Jun, WANG Jiadong. Treatment advance of secondary hyperthyroidism.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 36-39.

参考文献

[1] Slatopolsky E, Bown A, Dusso A. Role of phosphorus in pathogenesis of secondary hyperparathyroidism[J]. Am J Kidney Dis, 2001, 37:S54-S57.
[2] 孙鲁英,王梅,杨莉. 终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J]. 北京大学学报(医学版), 2005, 37(2):36-39. SNU Luying, WANG Mei, YANG Li. Study of calcium-phosphorous metabolism and intact parathyroid hormone levels in end stage renal disease patients[J]. J Peking Univ(Health Sci), 2005, 37(2):36-39.
[3] 贾彦诺,高志华,徐然东,等. 慢性肾衰竭继发性甲状旁腺功能亢进的相关因素分析及治疗[J]. 中国老年学杂志, 2015, 35(11):3182-3184.
[4] Nechama M, Uchida T, Mor Yosef-Levi I, et al. The peptidylprolyl isomerase Pin1 determines parathyroid hommne mRNA levels and stability in rat models of secondary hyperparathyroidism[J]. J Clin Invest, 2009, 119(10):3102-3114.
[5] 赵玉,张丽丽,曹平, 等.PIN1基因启动子区-667C>T多态性与慢性肾脏病伴继发性甲状旁腺功能亢进的相关性[J].肾脏病与透析肾移植杂志,2013,22(6):513-519. ZHAO Yu, ZHANG Lili, CAO Ping, et al. Correlation of PIN1 gene promoter region-667C > T polymorphism with secondary hyperparathyroidism of chronic kidney disease[J]. Chin J Nephrol Dialysis Transplant, 2013, 22(6):513-519.
[6] Komaba H, Fukagawa M. FGF23-Parathyroid interaction:implications in chronic kidney disease[J]. Kidney Int, 2010, 77(4):292-298.
[7] Kuro-o M. Klotho in health and disease[J]. Curr Opin Nephrol Hypertens, 2012, 21(4):362 -368.
[8] 冯嘉麟, 周秦毅, 陈隽, 等. 继发性甲状旁腺功能亢进外科治疗的疗效分析[J]. 中华耳鼻咽喉头颈外科杂志, 2015, 50(8):661-667. FENG Jialin, ZHOU Qinyi, CHEN Jun, et al. Therapeutic evaluation of surgical procedure in treatment of secondary hyperparathyroidism[J]. Chin J Otorhinolaryngol Head Neck Surg, 2015, 50(8):661-667.
[9] Parfrey P S, Drüeke T B, Block G A, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE)trial[J]. Clin J Am Soc Nephrol, 2015, 10(5):791-799.
[10] Perry C M, Plosker G L. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease[J]. Drugs, 2014, 74(7):771-792.
[11] Hutchison A J, Barnett M E, Krause R, et al. Long- term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment[J]. Nephron Clin Pract, 2008, 110(1):c15-23.
[12] Lund R J, Andress D L, Amdahl M, et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients[J]. Am J Nephrol, 2010, 31(2):165-170.
[13] Jun Chen, Jia-dong Wang. Radioguided parathyroidectomy in patients with secondary hyperparathyroidism due to chronic renal failure[J]. Nuclear Medicine Communications, 2014, 35:391-397.
[14] Johnson N A, Carty S E, Tublin M E. Parathyroid imaging[J]. Radiol Clin North Am, 2011, 49(3):489-509.
[15] 张庆,张青.甲状旁腺显像存在的问题及进展[J]. 江西医药,2006,41(11):920-921.
[16] 周建平,李昱骥,董明, 等. 原发性甲状旁腺功能亢进的定位诊断[J].中华普通外科杂志,2005,14(9):227-228. ZHOU Jianping, LI Yuji, DONG Ming, et al.Localizing diagnosis of primary hyperparathyroidism[J]. Chin J Gen Surgery, 2005, 14(9):227-228.
[17] Chen H, Sippel R S, Schaefer S. The effectiveness of radioguided parathyroidectomy in patients with negative technetium Tc 99m-sestamibi scan[J]. Arch Surg, 2009, 144(7):643-648.
[18] Harris R, Ryu H, Vu T, et al. Modern approach to surgical intervention of the thyroid and parathyroid glands[J]. Semin Ultrasound CT MR, 2012, 3(2):115-122.
[19] Richards M L, Wormuth J, Bingener J, et al. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?[J]. Surgery, 2006, 139(2):174-180.
[20] Shih M L, Duh Q Y, Hsieh C B, et al. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism[J]. World J Surg, 2009, 33(2):248-254.
[21] Chen J, Zhou Q Y, Wang J D. Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure: a meta-analysis[J]. Horm Metab Res, 2015, 47(9):643-651.
[22] Agha A, Loss M, Schlitt H J, et al. Recurrence of secondary hyperparathyroidism in patients after total parathyroidectomy with autotransplantation: technical and therapeutic aspects[J]. Eur Arch Otorhinolaryngol, 2012, 269(5):1519-1525.
[23] Goldstein R E, Billheimer D, Martin W H, et al. Sestamibi scanning and minimally invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement[J]. Ann Surg, 2003, 237(5):722-730.
[24] Rubello D, Giannini S, Martini C, et al. Minimally invasive radio-guided parathyroidectomy[J]. Biomed Pharmacother, 2006, 60(3):134-138.
[25] Cayo A, Chen H. Radioguided reoperative parathyroidectomy for persistent primary hyperparathyroidism[J]. Clin Nucl Med, 2008, 33(10):668-670.
[26] Fujii T, Yajima R, Yamaguchi S, et al. Could the eZ-SCOPE AN gamma camera replace intraoperative measurement of iPTH for PHPT?[J]. Inter Surgery, 2012, 97(2):99-103.
[27] Gencoglu E A, Aktas A. The efficacy of low and high dose(99m)Tc-MIBI protocols for intraoperative identification of hyperplastic parathyroid glands in secondary hyperparathyroidism[J]. Rev Esp Med Nucl Imagen Mol, 2014, 33(4):210-214.
[28] 张凌. 继发性甲状旁腺功能亢进的治疗策略[J]. 中华肾病研究电子杂志, 2015, 4(3):5-9. ZHANG Ling. Strategy for the treatment of secondary hyperparathyroidism[J]. Chin J Kid Dis Invest(Electr Ver), 2015, 4(3):5-9.

相关文章 15

[1]	王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74.
[2]	吴静,刘业海. 头颈部鳞状细胞癌的靶向治疗研究进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 97-102.
[3]	沈勤峰,沈小燕,朱荣强,蒋斐斐,郎军添. 鼻内镜下中鼻甲功能性部分切除治疗慢性鼻窦炎76例分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 82-85.
[4]	代亚错,李靖,万保罗,臧艳姿,黄颖铭. 个体化治疗咽喉部海绵状血管瘤二例[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 110-112.
[5]	刘义平,林远超. 负压引流防治腮腺术后涎瘘112例[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 65-67.
[6]	陈鸣,俞雪飞. 浅谈伴有变应性鼻炎的慢性鼻窦炎的治疗[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 18-22.
[7]	张桂敏,林鹏. 慢性鼻-鼻窦炎的内在型:从基础到临床[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 14-17.
[8]	覃纲,梁灼萍. 变应性真菌性鼻-鼻窦炎免疫治疗现状[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 23-26.
[9]	吴湘萍. 患者管理方式对变应性鼻炎舌下含服粉尘螨滴剂疗效的影响[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 68-72.
[10]	高进良,年婉清,李烁. 鼻内镜手术联合鼻用糖皮质激素治疗腺样体肥大性[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 38-42.
[11]	王仙,李颖,赵博军. 息肉样脉络膜血管病变诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 103-106.
[12]	吕丹,李明霞,马兰枝,张馨元,肖浩,陈飞,刘均,李珍. 累及纵膈的头颈部丛状I型神经纤维瘤病两例[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 82-86.
[13]	陈红,曹慧玲,窦鑫,高下. 右侧鼻腔小细胞神经内分泌癌一例并文献复习[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 89-92.
[14]	孙滨,郭伯敏,康杰,邓先兆,伍波,樊友本. 甲状腺未分化癌的规范化治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 16-20.
[15]	敬尚林. 儿童上气道咳嗽综合征临床诊疗现状[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 87-91.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed